×
About 4,755 results

ALLMedicine™ Essential Thrombocythemia Center

Research & Reviews  2,293 results

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
https://doi.org/10.1016/j.clml.2021.03.005
Clinical Lymphoma, Myeloma & Leukemia; Alshemmari SH, Rajan R et. al.

Apr 16th, 2021 - Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This study examines the driver mutatio...

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A...
https://doi.org/10.1002/ajh.26186
American Journal of Hematology; Gangat N, Guglielmelli P et. al.

Apr 12th, 2021 - Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven ...

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential...
https://doi.org/10.1016/j.clml.2021.02.011
Clinical Lymphoma, Myeloma & Leukemia; Yacoub A, Lyons R et. al.

Apr 11th, 2021 - Few data exist regarding the disease and clinical characteristics of patients with essential thrombocythemia (ET) in the United States. The ongoing, multicenter, noninterventional, prospective, Myelofibrosis and Essential Thrombocythemia Observati...

What factors determine the pregnancy outcome in patients with essential thrombocythemia?
https://doi.org/10.1080/14767058.2020.1863362
The Journal of Maternal-fetal & Neonatal Medicine : the O... Kwiatkowski J, Kuliszkiewicz-Janus M et. al.

Apr 1st, 2021 - Objectives: Treatment of essential thrombocythemia (ET) is particularly challenging in pregnancy due to the increased risk of thromboembolic complications. Therefore, the use of antithrombotic regimens are recommended in pregnant women with ET.Met...

MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house...
https://doi.org/10.1007/s12185-021-03134-6 10.1371/journal.pmed.0030270 10.1182/blood-2006-04-018879 10.1182/blood-2008-01-131664 10.1002/ajh.24338 10.1182/blood-2003-10-3471 10.3324/haematol.2009.005918 10.1182/blood.2019002561 10.1038/s41408-018-0159-3
International Journal of Hematology; Sugimoto Y, Nagaharu K et. al.

Mar 26th, 2021 - MPL exon 10 mutations are one of the driver mutations in essential thrombocythemia (ET) or myelofibrosis (MF). We have established an in-house MPL mutation analysis system, covering the entire region of MPL exon 10 by direct sequencing. Since 2009...

see more →

Guidelines  13 results

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 6th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
http://www.jnccn.org/content/15/10/1193.full
Mesa, R.,et al

Sep 30th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Onco...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.

Dec 13th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/14/12/1572.full
Mesa, R.,et al

Nov 30th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). The diagn.

see more →

Drugs  2 results see all →

Clinicaltrials.gov  2,361 results

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
https://doi.org/10.1016/j.clml.2021.03.005
Clinical Lymphoma, Myeloma & Leukemia; Alshemmari SH, Rajan R et. al.

Apr 16th, 2021 - Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This study examines the driver mutatio...

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A...
https://doi.org/10.1002/ajh.26186
American Journal of Hematology; Gangat N, Guglielmelli P et. al.

Apr 12th, 2021 - Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven ...

Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential...
https://doi.org/10.1016/j.clml.2021.02.011
Clinical Lymphoma, Myeloma & Leukemia; Yacoub A, Lyons R et. al.

Apr 11th, 2021 - Few data exist regarding the disease and clinical characteristics of patients with essential thrombocythemia (ET) in the United States. The ongoing, multicenter, noninterventional, prospective, Myelofibrosis and Essential Thrombocythemia Observati...

What factors determine the pregnancy outcome in patients with essential thrombocythemia?
https://doi.org/10.1080/14767058.2020.1863362
The Journal of Maternal-fetal & Neonatal Medicine : the O... Kwiatkowski J, Kuliszkiewicz-Janus M et. al.

Apr 1st, 2021 - Objectives: Treatment of essential thrombocythemia (ET) is particularly challenging in pregnancy due to the increased risk of thromboembolic complications. Therefore, the use of antithrombotic regimens are recommended in pregnant women with ET.Met...

MPL exon 10 mutations other than canonical MPL W515L/K mutations identified by in-house...
https://doi.org/10.1007/s12185-021-03134-6 10.1371/journal.pmed.0030270 10.1182/blood-2006-04-018879 10.1182/blood-2008-01-131664 10.1002/ajh.24338 10.1182/blood-2003-10-3471 10.3324/haematol.2009.005918 10.1182/blood.2019002561 10.1038/s41408-018-0159-3
International Journal of Hematology; Sugimoto Y, Nagaharu K et. al.

Mar 26th, 2021 - MPL exon 10 mutations are one of the driver mutations in essential thrombocythemia (ET) or myelofibrosis (MF). We have established an in-house MPL mutation analysis system, covering the entire region of MPL exon 10 by direct sequencing. Since 2009...

see more →

News  71 results

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

FDA approves fedratinib for myelofibrosis
https://www.mdedge.com/hematology-oncology/article/206575/cythemias/fda-approves-fedratinib-myelofibrosis?channel=50517
Jennifer Smith

Aug 16th, 2019 - The Food and Drug Administration has approved fedratinib (Inrebic), an oral JAK2/FLT3 inhibitor, to treat myelofibrosis. Fedratinib is approved to treat adults with intermediate-2 or high-risk primary or secondary (post–polycythemia vera or post–e.

New JAK2 Inhibitor Approved for Myelofibrosis
https://www.medpagetoday.com/hematologyoncology/hematology/81650

Aug 16th, 2019 - WASHINGTON -- The FDA approved the Janus kinase 2 (JAK2) inhibitor fedratinib (Inrebic) on Friday for adults with the rare bone marrow disease myelofibrosis. Support for the approval came largely from the phase III JAKARTA study, a randomized thre...

FDA Approves Fedratinib for the Treatment of Myelofibrosis
https://www.staging.medscape.com/viewarticle/916928

Aug 15th, 2019 - The US Food and Drug Administration (FDA) has approved fedratinib (Inrebic, Celgene) capsules for the treatment of adult patients with certain types of myelofibrosis. Fedratinib, a highly selective JAK2 inhibitor, is indicated for patients with in...

FDA Approves Fedratinib for the Treatment of Myelofibrosis
https://www.medscape.com/viewarticle/916928

Aug 15th, 2019 - The US Food and Drug Administration (FDA) has approved fedratinib (Inrebic, Celgene) capsules for the treatment of adult patients with certain types of myelofibrosis. Fedratinib, a highly selective JAK2 inhibitor, is indicated for patients with in...

see more →

Patient Education  15 results see all →